Trial Profile
Phase I Study of Oral Yeast Beta-Glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients With Metastatic Neuroblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2022
Price :
$35
*
At a glance
- Drugs Beta glucan (Primary) ; Monoclonal antibody 3F8 (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 04 Mar 2022 Status changed from active, no longer recruiting to completed.
- 01 Sep 2021 Planned End Date changed from 1 Aug 2021 to 1 Aug 2022.
- 01 Sep 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2022.